medium and incubated at 37°C for 24h followed by plating onto 7H11/ADC plates containing kanamycin at 20 9 4 µg/ml, hygromycin at 50 µ g/ml, and X-Gal at 50µg/ml. The plates were incubated at 37°C for 4-5 weeks until 9 5 colonies appeared. Single cross-over transformants were picked and restreaked onto fresh 7H11/ADC without 9 6 any antibiotics and incubated at 37°C for 2-3 weeks. A loopful of bacteria from the plates were resuspended in 1 9 7 ml of 1-mm glass beads and 3 mL of 7H9/ADC/Tween 80 and vortexed vigorously. Serial dilutions were plated 9 8 onto plates containing X-gal with and without sucrose at 2% (w/v) and incubated for 4 weeks until the potential 9 9 double cross-over transformants appeared. The kanamycin-sensitive colonies were screened using colony-PCR 0 0 followed by DNA sequencing to confirm the desired point mutation being constructed in the genome of M. drug concentrations were used: SM (0.5, 1, 2, 4, 8 µg/ml). INH (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32 , 64 µg/ml), 0 8 PZA (50, 100, 200, 400, 800, 1600 µg/ml, pH 6.0), p-aminosalicylic acid (PAS) (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 0 9 128 µg/ml), rifampicin (0.25, 0.5, 1, 2, 4 µg/ml), ethambutol (1, 2, 4, 8, 16 M. tuberculosis H37Ra, grown in in7H9/ADC/Tween 80 medium, were harvested and the cell pellets were 1 8 resuspended in 7H9 medium (pH 6.6) at 5×10 8 cells/ml. The PZA uptake and accumulation study was 1 9
performed as described previously (13). Briefly, [ 14 C]PZA, purchased from Vitrax (Placentia, CA, USA), was 2 0 added to the cell suspensions to a concentration of 1 µCi/ml and the cell mixtures were incubated at 37°C. At 2 1 different time points, 50 µl portions were removed and washed with 1×PBS buffer (pH 6.6) with 0.1M LiCl by 2 2 filtration on 0.45µm-pore-size nitrocellulose filters by using a vacuum pump. The amount of radioactivity 2 3 associated with the bacterial cells was determined by autoradiography and scintillation counting. resistance, we performed database search for mutations in the efflux pump Rv1258c (Tap) among clinical 3 0
isolates whose whole genome sequences are deposited in the PubMed NCBI database. A number of single To address the role of the identified point mutations in Rv1258c, we attempted to construct the point mutations D23V, V219A and S292L by site-directed mutagenesis by PCR and the altered mutant sequences were 3 8 confirmed to be correct by DNA sequencing. We were able to successfully construct Rv1258c point mutations Rv1258c point mutation V219A and S292L mutants to various drugs as described below. showed that Rv1258c S292L mutant was more resistant to streptomycin, isoniazid, and pyrazinamide than the 4 6 parent strain H37Ra (Table 1) . However, Rv1258c V219A point mutation caused a lower level of resistance to 4 7 the above drugs than the S292L mutation. It is noteworthy that while V219A mutation only caused a marginal (MIC=32 µg/ml) ( Table 1 ). This latter finding is significant as it offers a possible alternative mechanism of INH clarithromycin ( Fig. 1-4 , Table 1 ). Our finding that Rv1258c S292L point mutation conferred resistance to shown by autoradiography (A) and scintillation counting (B). The S292L mutant accumulated less drug than the V219A mutant, while both mutants accumulated less drug than the parent strain M. tuberculosis H37Ra.
